ArticleJTO clinical and research reports2025

Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC.

Omar Elghawy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.